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Chronic myeloid leukemia (CML) is effectively treated by tyrosine kinase inhibitors (TKIs). Rarely, CML cases
develop TKI resistance through acquisition of compound mutations. In this issue of Cancer Cell, Zabriskie
and colleagues study how structural changes caused by compound mutations cause clinically relevant
changes in TKI sensitivity.Chronic myeloid leukemia (CML) is a rare
clonal myeloproliferative disease, occur-
ring roughly in 2 of 100,000 persons,
but it has dramatically shaped the world
of molecular oncology and targeted ther-
apy. CML was the first disease in which
a unique chromosomal translocation,
t(9;22), the so called ‘‘Philadelphia chro-
mosome’’ (because it was discovered at
the Winstar Institute in Philadelphia), was
discovered. At the genetic level, it was es-
tablished that the translocation resulted in
the BCR-ABL chimeric gene; this unique
and universal event (because all CML
cases have the rearranged BCR-ABL)
then became a target for therapy and a
sensitive marker for disease monitoring.
The aberrant activity of the tyrosine ki-
nase ABL, when placed in the chimeric
BCR-ABL context, drives the pathogen-
esis of CML. The development of tyrosine
kinase inhibitors (TKIs) that inhibit ABL
has dramatically altered the natural his-
tory of CML. Before TKIs, the median sur-
vival of newly diagnosed CML patients
was roughly 5 years; with TKI therapy,
the 10 year survival rate is >80% (Druker
et al., 2006). Indeed, the therapy is so
effective that some patients become free
of any detectable disease, and, in some
patients, TKI therapy can be discontinued
without relapse. The evolution of treat-
ment strategies in CML in a little over a
decade is nothing short of remarkable,
and the success of TKI therapy is the
benchmark against all other targeted ther-
apy is judged.
There are several TKIs now in clinical
use for treating CML. Nonetheless, some
CML patients do become resistant to
TKI therapy (Apperley 2007). Often, TKI
resistance is caused by single amino
acid mutations in the ABL domain of theBCR-ABL, which changes the protein
conformation to limit or exclude the TKI
binding. Some of these point mutations
have different sensitivities to different
TKIs, for example, insensitive to imatinib
but still sensitive to dasatinib. However,
the T315I mutation is resistant across a
broad range of TKIs and is only effectively
inhibited by the recently Food and Drug
Administration approved ponatinib, which
has activity against all known single amino
acid ABL mutations that are resistant to
clinical TKIs (Cortes et al., 2012; O’Hare
et al., 2009).
As the Borg will ruefully acknowledge,
resistance is not futile, and, in CML, the
strong selective pressures of ponatinib
have led to cases of resistance involving
compound mutations in ABL (Khorashad
et al., 2013; Soverini et al., 2013). These
are multiple point mutations occurring in
the same BCR-ABL allele, as opposed to
multiple clones with different mutations.
This phenomenon has been seen in other
diseases treated with targeted therapy
(Smith et al., 2013) and may become an
increasing common phenomenon as
more cancers are treated with targeted
therapy and tumors develop cleaver tac-
tics to evade selective pressure. In this
issue of Cancer Cell, Zabriskie et al.
(2014) study a series of CML cases with
compound mutations, and, in a series of
logical, thoughtful, and well-executed ex-
periments, build a solid understanding of
how the structure and function of these
mutations drive drug susceptibility and,
ultimately, patient response to therapy.
The authors first surveyed the land-
scape of compound mutations to under-
stand the patterns of mutations, because
one would expect that only certain combi-
nation ofmutations would cause sufficientCancer Cell 26, Sstructural change in BCR-ABL to prevent
kinase inhibition by TKIs. While >100
different kinase point mutations have
been reported, only 12 positions have
been involved in the vast majority of
compound mutations. The authors then
looked at over 400 patients enrolled in a
phase 2 trial of ponatinib for patients
who were resistant or intolerant to the
‘‘second generation’’ TKIs dasatinib or ni-
lotinib or had the resistant T315I mutation.
Many of these patients had failed two
different TKIs before being in the study,
so their diseases had already passed
through a rigid test of natural selection,
thus enriching for complicated kinase
dependent or independent mechanisms
of resistance. Sixteen patients had com-
pound mutations evident at the end of
treatment (3 cases ended treatment
because of toxicity, 13 from lack of effi-
cacy of ponatinib), and, remarkably, the
compound mutations involved at least 2
of the key positions in all but one case.
To further understand the relationship
of compound mutations and sensitivity
to TKIs, the authors then performed prolif-
eration assays, comparing the growth of
Ba/F3 cells expressing ectopic wild-type
BCR-ABL to those expressing ectopic
BCR-ABL containing a spectrum of
single and compound mutations. While
ponatinib inhibited the growth of cells ex-
pressing any single mutations (including
the T315I), its effectiveness was greatly
decreased in T315I-containing com-
pound mutations. This was borne out in
the experience of patients in the clinical
trial, where patients whose CML had
baseline BCR-ABL compound mutations
involving T315I or a baseline BCR-ABL
T315I mutation and evolved a clone con-
taining an additional BCR-ABL mutationeptember 8, 2014 ª2014 Elsevier Inc. 305
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However, 22 cases of compound muta-
tions without T315I patterns of variable
effectiveness was demonstrated across
the panel of TKIs, which suggests that
early detection of compound mutations
could be combined with sensitivity
studies to shape a therapeutic change in
TKIs and thus abort the emergence of
resistant clones.
Computer modeling suggested the
impact of compoundmutations on TKI ac-
tivity. The proliferation studies noted
above found that, for compound muta-
tions not containing T315I, ponatinib
anddasatinib had similar activities, except
with the Y253H/E55V compound muta-
tion, where dasatinib is considerably
more active. The binding sites of ponatinib
and dasatinib are known to be different;
can modeling explain the difference?
Indeed, it can; molecular dynamic simula-
tions showed that Y253H and E255V mu-
tations force a shift in the P loop of the
ABL kinase domain, obstructing the pona-
tinib binding site. Similar simulations sug-306 Cancer Cell 26, September 8, 2014 ª201gested poor ponatinib activity in clinically
relevant disease evolution, such as thedif-
ference in the binding domains of a single
T315I and the resistant T315I/E255V
mutation. Thus, the authors elegantly fol-
lowed the interplay of structure, in vitro
and in vivo function.
Why is this study important? First, it is a
demonstration of how clinical material,
wet bench work, and computer modeling
can be melded to develop a clear under-
standing of clinically important biology.
Second, it provides a clear roadmap of
how future studies can be performed to
understand disease resistance. As ‘‘tar-
geted therapy’’ becomes an increasing
reality in cancer care, it will become
increasingly important to understand
and anticipate how Darwinian selection
will select for resistance. This manuscript
helps prepare us for that future.REFERENCES
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A better understanding of genetic interactions in cancer might help identify new therapeutic approaches that
exploit the concept of synthetic lethality. Ruppin and colleagues have developed a new computational
method, DAISY, that predicts such interactions and potentially facilitates the delineation and validation of
comprehensive genetic interaction networks.Most of the major recent advances in the
development of targeted therapies for
cancer have originated from the identifica-
tion and exploitation of genetic depen-
dencies that operate specifically in tumor
cells. Many of these dependencies are
considered as oncogene addiction ef-
fects, where tumor cells become reliant
upon the activity of key driver genes
such as BCR-ABL and EGFR; pharma-cological inhibition of these drivers has
therapeutic benefit. Other dependencies
include those that arise as a consequence
of the ‘‘cancer state,’’ also called nonon-
cogene addictions (Luo et al., 2009). How-
ever, inmany cases these gene addictions
are difficult to target directly with drugs.
Moreover, there aremany recessive driver
mutations in tumor genomes, the so-
called tumor suppressors, in which absentor reduced gene function contributes to
tumorigenesis. Synthetic lethality (SL)
provides a potential approach to targeting
these latter two classes of alterations. The
term describes the relationship between
two genes whereby individual defects in
either gene are compatible with cell
viability, but the synthesis or combination
of gene defects results in cell death (Ash-
worth et al., 2011). Recently the
